Schindellegi, Switzerland, February 24th, 2021
Zynnon is pleased to announce that, in December 2020, it was awarded initial support from Innosuisse (Swiss Innovation Agency) for the development of its new medical device, Lieberty. As part of a rigorous application process, this is a crucial first step towards identifying the most appropriate backing from the agency.
Khaled Abousaleh, CEO of Zynnon, is delighted with this new development: “Building on the experience and success of my previous business venture, and a strong desire to make a positive contribution in response to the health challenges facing our society, we have launched a very ambitious project. Being able to rely on the expertise of an Innosuisse licensed coach gives us a much appreciated boost to push ahead with our innovative solution to mitigate pandemic risk.”
Innosuisse is the Swiss Innovation Promotion Agency. It is a federal entity under public law with a separate legal personality. Innosuisse’s role is to promote science-based innovation in the interests of industry and society in Switzerland. Innosuisse especially promotes the partnership between academia and the market with innovation projects, networking, training and coaching, laying the groundwork for successful Swiss start-ups, products and services. It provides considerable benefits for a prosperous and sustainable economy.
Zynnon (www.zynnon.com) is a start-up focused on improving and protecting people’s health using the Internet of Medical Things (IoMT). Zynnon’s mission is to provide AI-driven data analytics solutions for the consumer health market based on data insights gathered from our network of connected medical devices.
Its first product line, Lieberty, will combine affordable high-tech medical devices with associated services and solutions to protect people during viral outbreaks by reducing the risk of infection. Designed and manufactured in Switzerland, Lieberty’s cordless non-contact temperature screening devices will allow businesses and communities to resume their regular pre-pandemic activities with a significantly higher level of safety.
For further information:
CFO & Investor Relations Manager